The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials

BMC Nephrology

Volumn 17, Issue 1, 2016, Pages 1-8

  Schulman, Gerald ^a   Berl, Tomas ^b   Beck, Gerald J ^c   Remuzzi, Giuseppe ^d,e,f   Ritz, Eberhard ^g   Shimizu, Miho ^h   Shobu, Yuko ⁱ   Kikuchi, Mami ⁱ  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

ⁱ KUREHA CORPORATION   (Japan)

Author keywords

AST 120; Chronic kidney disease; Clinical trial; Spherical carbon adsorbent; Uremic toxin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AST 120; C REACTIVE PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; CARBON; OXIDE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES; AGED; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; KAPLAN MEIER METHOD; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; CARBON; CREATININE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OXIDES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 84995376520     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-016-0357-9     Document Type: Article

References (26)

1. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2012. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands. 2014.
2. United States Renal Data System, 2014 Annual Data Report. Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2014.
3. American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care. 2014;37 Suppl 1:S14-80.
4. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 1999;159:1873-80.
5. Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy. 2008;6:103-12.
6. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs of end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care. 2003;26:683-7.
7. Hayashino Y, Fukuhara S, Akizawa T, et al. CAP-KD study group. Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease. Diabetes Res Clin Pract. 2010;90:154-9.
8. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850-86.
9. National Kidney Foundation. KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43 Suppl 1:S1-S290.
10. Andrassy KM. National Kidney Foundation: comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'. Kidney Int. 2013;84:622-3.
11. Akizawa T, Koide K, Koshikawa S. Effects of Kremezin on patients with chronic renal failure results of a nationwide clinical study. Kidney Dial. 1998;45:373-88 [Japanese].
12. Schulman G, Vanholder R, Niwa T. AST-120 for the management of progression of chronic kidney disease. Int J Nephrol Renovasc Dis. 2014;7:49-56.
13. Niwa T, Yazawa T, Ise M, et al. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats. Nephron. 1991;57:84-8.
14. Schulman G, Berl T, Beck GJ, et al. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J Am Soc Nephrol. 2015;26:1732-46.
15. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518-31.
16. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, et al. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis. 2014;63:244-50.
17. Inker LA, Lambers Heerspink HJ, Mondal H, et al. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis. 2014;64:848-59.
18. Lambers Heerspink HJ, Tighiouart H, Sang Y, et al. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am J Kidney Dis. 2014;64:860-6.
19. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis. 2006;48:S1-S322.
20. Stel VS, Tomson C, Ansell D, et al. Level of renal function in patients starting dialysis: and ERA-EDTA Registry study. Nephrol Dial Transplant. 2010;25:3315-25.
21. Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev. 2009;3:CD001892.
22. Ladhani M, Craig JC, Irving M, et al. Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2016. doi:10.1093/ndt/gfw075.
23. Keane WF, Brenner BM, Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int. 2003;53:1499-507.
24. Schulman G, Agarwal R, Acharya M, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis. 2006;47:565-77.
25. Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diabetes Res Clin Pract. 2009;83:220-6.
26. Barreto FC, Barreto DV, Liabeuf S, et al. European Uremic Toxin Work Group (EUTox): serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4:1551-8.